Roche Holding AG (SIX: ROP.SW) Stock Competitors & Peer Comparison

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, LLY.SW has a market cap of 891.7B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while LLY.SW trades at CHF 1,000.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas LLY.SW's P/E ratio is 39.73. In terms of profitability, ROP.SW's ROE is +0.37%, compared to LLY.SW's ROE of +0.93%. Regarding short-term risk, ROP.SW is more volatile compared to LLY.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check LLY.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, JNJ.SW has a market cap of 507.8B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while JNJ.SW trades at CHF 210.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas JNJ.SW's P/E ratio is 23.97. In terms of profitability, ROP.SW's ROE is +0.37%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, ROP.SW is more volatile compared to JNJ.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check JNJ.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, RO.SW has a market cap of 297.6B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while RO.SW trades at CHF 379.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas RO.SW's P/E ratio is 22.76. In terms of profitability, ROP.SW's ROE is +0.37%, compared to RO.SW's ROE of +0.37%. Regarding short-term risk, ROP.SW is more volatile compared to RO.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check RO.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, ROG.SW has a market cap of 256.6B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while ROG.SW trades at CHF 322.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas ROG.SW's P/E ratio is 20.11. In terms of profitability, ROP.SW's ROE is +0.37%, compared to ROG.SW's ROE of +0.41%. Regarding short-term risk, ROP.SW is more volatile compared to ROG.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check ROG.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, NOVN.SW has a market cap of 242.2B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while NOVN.SW trades at CHF 127.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas NOVN.SW's P/E ratio is 18.55. In terms of profitability, ROP.SW's ROE is +0.37%, compared to NOVN.SW's ROE of +0.30%. Regarding short-term risk, ROP.SW is more volatile compared to NOVN.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check NOVN.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, GILD.SW has a market cap of 143.2B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while GILD.SW trades at CHF 115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas GILD.SW's P/E ratio is 21.45. In terms of profitability, ROP.SW's ROE is +0.37%, compared to GILD.SW's ROE of -0.17%. Regarding short-term risk, ROP.SW is more volatile compared to GILD.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check GILD.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, GSK.SW has a market cap of 101.6B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while GSK.SW trades at CHF 19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas GSK.SW's P/E ratio is 18.76. In terms of profitability, ROP.SW's ROE is +0.37%, compared to GSK.SW's ROE of +0.38%. Regarding short-term risk, ROP.SW is not fully comparable compared to GSK.SW. This indicates unavailable risk data in terms of short-term price fluctuations for ROP.SW.Check GSK.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, BMY.SW has a market cap of 87.7B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while BMY.SW trades at CHF 52.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas BMY.SW's P/E ratio is 10.13. In terms of profitability, ROP.SW's ROE is +0.37%, compared to BMY.SW's ROE of +0.45%. Regarding short-term risk, ROP.SW is more volatile compared to BMY.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check BMY.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, BAYN.SW has a market cap of 44.8B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while BAYN.SW trades at CHF 45.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas BAYN.SW's P/E ratio is 10.16. In terms of profitability, ROP.SW's ROE is +0.37%, compared to BAYN.SW's ROE of -0.06%. Regarding short-term risk, ROP.SW is more volatile compared to BAYN.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check BAYN.SW's competition here

Roche Holding AG (SIX: ROP.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROP.SW stands at 299B. In comparison, BIIB.SW has a market cap of 20.8B. Regarding current trading prices, ROP.SW is priced at CHF 375.60 on the SIX, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROP.SW currently has a P/E ratio of 19.30, whereas BIIB.SW's P/E ratio is 11.19. In terms of profitability, ROP.SW's ROE is +0.37%, compared to BIIB.SW's ROE of +0.05%. Regarding short-term risk, ROP.SW is more volatile compared to BIIB.SW. This indicates higher risk in terms of short-term price fluctuations for ROP.SW.Check BIIB.SW's competition here